2. Search Result
Search Result
Results for "

CaV3

" in MedChemExpress (MCE) Product Catalog:

49

Inhibitors & Agonists

2

Fluorescent Dye

3

Biochemical Assay Reagents

4

Peptides

4

Natural
Products

12

Isotope-Labeled Compounds

2

Antibodies

1

Oligonucleotides

2

GMP Molecules

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-B0166
    L-Ascorbic acid
    Maximum Cited Publications
    80 Publications Verification

    L-Ascorbate; Vitamin C

    		 Environmental Pollutants Endogenous Metabolite Calcium Channel Reactive Oxygen Species (ROS) Apoptosis Neurological Disease Metabolic Disease Cancer
    L-Ascorbic acid (L-Ascorbate), an electron donor, is an endogenous antioxidant agent. L-Ascorbic acid inhibits selectively Cav3.2 channels with an IC50 of 6.5 μM. L-Ascorbic acid is also a collagen deposition enhancer and an elastogenesis inhibitor [3]. L-Ascorbic acid exhibits anti-cancer effects through the generation of reactive oxygen species (ROS) and selective damage to cancer cells .
    L-Ascorbic acid
  • HY-B0166A
    L-Ascorbic acid sodium salt
    Maximum Cited Publications
    80 Publications Verification

    Sodium ascorbate; Sodium L-ascorbate; Vitamin C sodium salt

    		 Environmental Pollutants Apoptosis Endogenous Metabolite Calcium Channel Reactive Oxygen Species (ROS) Cancer
    L-Ascorbic acid sodium salt (Sodium ascorbate), an electron donor, is an endogenous antioxidant agent. L-Ascorbic acid sodium salt selectively inhibits Cav3.2 channels with an IC50 of 6.5 μM. L-Ascorbic acid sodium salt is also a collagen deposition enhancer and an elastogenesis inhibitor [3].
    L-Ascorbic acid sodium salt
  • HY-B0166R
    L-Ascorbic acid (Standard)
    2 Publications Verification

    L-Ascorbate (Standard); Vitamin C (Standard)

    		 Reference Standards Reactive Oxygen Species (ROS) Calcium Channel Apoptosis Endogenous Metabolite Neurological Disease Metabolic Disease Cancer
    L-Ascorbic acid (Standard) is the analytical standard of L-Ascorbic acid. This product is intended for research and analytical applications. L-Ascorbic acid (L-Ascorbate), an electron donor, is an endogenous antioxidant agent. L-Ascorbic acid inhibits selectively Cav3.2 channels with an IC50 of 6.5 μM. L-Ascorbic acid is also a collagen deposition enhancer and an elastogenesis inhibitor [3]. L-Ascorbic acid exhibits anti-cancer effects through the generation of reactive oxygen species (ROS) and selective damage to cancer cells .
    L-Ascorbic acid (Standard)
  • HY-111828
    TTA-A2
    1 Publications Verification

    		 Calcium Channel Neurological Disease
    TTA-A2 is a potent, selective and orally active t-type voltage gated calcium channel antagonist with reduced pregnane X receptor (PXR) activation. TTA-A2 is equally potent against the Cav3.1 (a1G) and Cav3.2 (a1H) channels with IC50 values of 89 nM and 92 nM, respectively, at -80 and -100 mV holding potentials. TTA-A2 can be used for the research of a variety of human neurological diseases, including sleep disorders and epilepsy .
    TTA-A2
  • HY-B0166G
    L-Ascorbic acid

    L-Ascorbate; Vitamin C

    		 Reactive Oxygen Species (ROS) Calcium Channel Apoptosis Endogenous Metabolite Neurological Disease Metabolic Disease Cancer
    L-Ascorbic acid (L-Ascorbate) (GMP) is Ascorbic acid (HY-B0166) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. L-Ascorbic acid is an inhibitor of Cav 3.2 channels .
    L-Ascorbic acid
  • HY-103309
    ML218
    2 Publications Verification

    		 Calcium Channel Neurological Disease
    ML218 is a potent, selective and orally active T-type Ca 2+ channels (Cav3.1, Cav3.2, Cav3.3) inhibitor with IC50s of 310 nM and 270 nM for Cav3.2 and Cav3.3, respectively. ML218 inhibits the burst activity in subthalamic nucleus (STN) neurons. ML218 has no significant inhibition of L- or N-type calcium channels, KATP or hERG potassium channels. ML218 can penetrate the blood-brain barrier .
    ML218
  • HY-132184
    5,6-Epoxyeicosatrienoic acid

    5,6-EET; (±)5,6-EpETrE

    		 Adrenergic Receptor Calcium Channel Endocrinology
    5,6-Epoxyeicosatrienoic acid (5,6-EET; (±)5,6-EpETrE) is a fully racemic version of the enantiomeric forms biosynthesized from arachidonic acid by cytochrome P450 enzymes. In solution, 5,6-Epoxyeicosatrienoic acid degrades into 5,6-DiHET and 5,6-δ-lactone, which can be converted to 5,6-DiHET and quantified by GC-MS. In neuroendocrine cells, such as the anterior pituitary and pancreatic islets, 5,6-Epoxyeicosatrienoic acid has been implicated in the mobilization of calcium and hormone secretion. 5,6-Epoxyeicosatrienoic acid is an inhibitor of T-type voltage-gated calcium channels (Cav3) that inhibits isoforms Cav3.1, Cav3.2 (IC50=0.54 μM), and Cav3. and decreases nifedipine-resistant phenylephrine-induced vasoconstriction in isolated mouse mesenteric arteries via Cav3.2 blockade when used at a concentration of 3 μM. In addition, it is a substrate of COX-1 and COX-2.
    5,6-Epoxyeicosatrienoic acid
  • HY-W011235
    Norfluoxetine hydrochloride

    		5-HT Receptor Calcium Channel Drug Metabolite Cardiovascular Disease Neurological Disease
    Norfluoxetine hydrochloride is an active N-demethylated metabolite of Fluoxetine. Fluoxetine is a selective serotonin (5-HT) reuptake inhibitor that is metabolized to Norfluoxetine hydrochloride by cytochrome P450 (CYP) 2D6, CYP2C19, and CYP3A4. Norfluoxetine hydrochloride inhibits 5-HT uptake and inhibits CaV3.3 T current (IC50 = 5 μM). Norfluoxetine hydrochloride has anticonvulsant activity [3] .
    Norfluoxetine hydrochloride
  • HY-B0166S
    L-Ascorbic acid-13C6

    L-Ascorbate-13C6; Vitamin C-13C6

    		 Isotope-Labeled Compounds Reactive Oxygen Species (ROS) Calcium Channel Apoptosis Endogenous Metabolite Neurological Disease Metabolic Disease Cancer
    L-Ascorbic acid- 13C6 is the 13C-labeled L-Ascorbic acid. L-Ascorbic acid (L-Ascorbate), an electron donor, is an endogenous antioxidant agent. L-Ascorbic acid inhibits selectively Cav3.2 channels with an IC50 of 6.5 μM. L-Ascorbic acid is also a collagen deposition enhancer and an elastogenesis inhibitor [3]. L-Ascorbic acid exhibits anti-cancer effects through the generation of reactive oxygen species (ROS) and selective damage to cancer cells .
    L-Ascorbic acid-13C6
  • HY-120597
    SAK3

    		Calcium Channel Neurological Disease
    SAK3 is a potent T-type voltage-gated Ca 2+ channels (T-VGCCs) enhancer. SAK3 enhances Cav3.1 and Cav3.3 T-type Ca 2+ channel currents. Acute SAK3 administration improves memory deficits in olfactory-bulbectomized mice . SAK3 inhibits amyloid β plaque formation in APP-KI mice by activating the proteasome activity .
    SAK3
  • HY-B0166S8
    L-Ascorbic acid-13C6-1

    L-Ascorbate-1; Vitamin C-13C6-1

    		 Isotope-Labeled Compounds Endogenous Metabolite Reactive Oxygen Species (ROS) Calcium Channel Apoptosis Cancer
    L-Ascorbic acid- 13C6-1 (L-Ascorbate-1; Vitamin C- 13C6-1) is a 13C labeled L-Ascorbic acid (HY-B0166) . L-Ascorbic acid (L-Ascorbate), an electron donor, is an endogenous antioxidant agent. L-Ascorbic acid inhibits selectively Cav3.2 channels with an IC50 of 6.5 μM. L-Ascorbic acid is also a collagen deposition enhancer and an elastogenesis inhibitor [3] . L-Ascorbic acid exhibits anti-cancer effects through the generation of reactive oxygen species (ROS) and selective damage to cancer cells .
    L-Ascorbic acid-13C6-1
  • HY-B0166S6
    L-Ascorbic acid-d2

    L-Ascorbate-d2; Vitamin C--d2

    		 Apoptosis Calcium Channel Endogenous Metabolite Reactive Oxygen Species (ROS) Neurological Disease Metabolic Disease Cancer
    L-Ascorbic acid-d2 is the deuterium labeled L-Ascorbic acid. L-Ascorbic acid (L-Ascorbate), an electron donor, is an endogenous antioxidant agent. L-Ascorbic acid inhibits selectively Cav3.2 channels with an IC50 of 6.5 μM. L-Ascorbic acid is also a colla
    L-Ascorbic acid-d2
  • HY-B0166S1
    L-Ascorbic acid-13C

    L-Ascorbate-13C; Vitamin C-13C

    		 Isotope-Labeled Compounds Reactive Oxygen Species (ROS) Calcium Channel Apoptosis Endogenous Metabolite Neurological Disease Metabolic Disease Cancer
    L-Ascorbic acid- 13C is the 13C-labeled L-Ascorbic acid. L-Ascorbic acid (L-Ascorbate), an electron donor, is an endogenous antioxidant agent. L-Ascorbic acid inhibits selectively Cav3.2 channels with an IC50 of 6.5 μM. L-Ascorbic acid is also a collagen deposition enhancer and an elastogenesis inhibitor [3]. L-Ascorbic acid exhibits anti-cancer effects through the generation of reactive oxygen species (ROS) and selective damage to cancer cells .
    L-Ascorbic acid-13C
  • HY-P3269
    Calciseptine

    		Calcium Channel Cardiovascular Disease
    Calciseptine is a natural polypeptide toxin found in the venom of the black mamba snake (Dendroaspis p. polylepis). Calciseptine is a highly effective and selective blocker of the L-type channel of the Cav1.2 subtype, with an IC50 value of 92 nM. Calciseptine has no effect on Cav3.1, Cav2.2, Cav2.1, Cav1.1, voltage-sensitive sodium channels and potassium channels. Calciseptine exhibits negative inotropic and negative relaxant effects on mice, and does not affect heart rate or the action potential of sinoatrial node pacemaker cells. Calciseptine can be used for research on cardiovascular diseases[1].
    Calciseptine
  • HY-RS01988
    CAV3 Human Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    CAV3 Human Pre-designed siRNA Set A contains three designed siRNAs for CAV3 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    CAV3 Human Pre-designed siRNA Set A
    CAV3 Human Pre-designed siRNA Set A
  • HY-B0166S3
    L-Ascorbic acid-13C-2

    L-Ascorbate-13C-2; Vitamin C-13C-2

    		 Apoptosis Calcium Channel Endogenous Metabolite Reactive Oxygen Species (ROS) Neurological Disease Metabolic Disease Cancer
    L-Ascorbic acid- 13C-2 is the 13C labeled L-Ascorbic acid. L-Ascorbic acid (L-Ascorbate), an electron donor, is an endogenous antioxidant agent. L-Ascorbic acid inhibits selectively Cav3.2 channels with an IC50 of 6.5 μM. L-Ascorbic acid is also a collagen
    L-Ascorbic acid-13C-2
  • HY-147638
    MONIRO-1

    		Calcium Channel Neurological Disease
    MONIRO-1 is a T-type and N-type calcium channel blocker with IC50 values of 34, 3.3, 1.7 and 7.2 µM against hCav2.2, hCav3.1, hCav3.2 and hCav3.3, respectively. MONIRO-1 has low activity against L-type calcium channels. MONIRO-1 can be used for the study of pain and epilepsy .
    MONIRO-1
  • HY-115681
    (2R/S)-6-PNG
    1 Publications Verification

    6-Prenylnaringenin; (±)-6-Prenylnaringenin

    		 Calcium Channel Neurological Disease
    (2R/S)-6-PNG (6-Prenylnaringenin) is a potent and reversible Cav3.2 T-type Ca 2+ channels (T-channels) blocker. (2R/S)-6-PNG can penetrate the blood-brain barrier (BBB). (2R/S)-6-PNG suppresses neuropathic and visceral pain in mice .
    (2R/S)-6-PNG
  • HY-151452
    Cav 3.2 inhibitor 3

    		Calcium Channel Neurological Disease
    Cav 3.2 inhibitor 3 (Compound 4) is a potent Cav3.2 T-type Ca 2+ channel inhibitor with an IC50 of 0.1534 μM, and has little binding affinity to D2 receptors .
    Cav 3.2 inhibitor 3
  • HY-112499S
    Menaquinone-7-d7

    Vitamin K2-7-d7; Vitamin K2(35)-d7; Vitamin MK-7-d7

    		 Isotope-Labeled Compounds Cardiovascular Disease
    Menaquinone-7-d7 is the deuterium labeled Menaquinone-7. Menaquinone-7 (Vitamin K2-7), belongs to a class of K2-vitamin homologs, is originally discovered as the anti-hemorrhagic factors . Menaquinone-7 (Vitamin K2-7) is identified as the most bioactive cofactor for the carboxylation reaction of Gla-proteins . Supplementation with Menaquinone-7 (Vitamin K2-7) is a pharmacological option for activating matrix Gla protein and intervening in the progression of calcific aortic valve stenosis (CAVS) .
    Menaquinone-7-d7
  • HY-B0166GL
    L-Ascorbic acid (GMP Like)

    L-Ascorbate (GMP Like); Vitamin C (GMP Like)

    		 Reactive Oxygen Species (ROS) Apoptosis Calcium Channel Endogenous Metabolite Neurological Disease Metabolic Disease Cancer
    L-Ascorbic acid (GMP Like) is the GMP Like class L-Ascorbic acid (HY-B0166). L-Ascorbic acid (L-Ascorbate, Vitamin C), an electron donor, is an endogenous antioxidant agent. L-Ascorbic acid inhibits selectively Cav3.2 channels with an IC50 of 6.5 μM. L-Ascorbic acid is also a collagen deposition enhancer and an elastogenesis inhibitor [3]. L-Ascorbic acid exhibits anti-cancer effects through the generation of reactive oxygen species (ROS) and selective damage to cancer cells .
    L-Ascorbic acid (GMP Like)
  • HY-B0166S2
    L-Ascorbic acid-13C-1

    L-Ascorbate-13C-1; Vitamin C-13C-1

    		 Apoptosis Calcium Channel Endogenous Metabolite Reactive Oxygen Species (ROS) Neurological Disease Metabolic Disease Cancer
    L-Ascorbic acid- 13C-1 is the 13C labeled L-Ascorbic acid. L-Ascorbic acid (L-Ascorbate), an electron donor, is an endogenous antioxidant agent. L-Ascorbic acid inhibits selectively Cav3.2 channels with an IC50 of 6.5 μM. L-Ascorbic acid is also a collagen
    L-Ascorbic acid-13C-1
  • HY-B0166S5
    L-Ascorbic acid-13C-4

    L-Ascorbate-13C-4; Vitamin C-13C-4

    		 Isotope-Labeled Compounds Apoptosis Calcium Channel Endogenous Metabolite Reactive Oxygen Species (ROS) Neurological Disease Metabolic Disease Cancer
    L-Ascorbic acid- 13C-4 is the 13C labeled L-Ascorbic acid. L-Ascorbic acid (L-Ascorbate), an electron donor, is an endogenous antioxidant agent. L-Ascorbic acid inhibits selectively Cav3.2 channels with an IC50 of 6.5 μM. L-Ascorbic acid is also a collag
    L-Ascorbic acid-13C-4
  • HY-B0166AR
    L-Ascorbic acid sodium salt (Standard)

    Sodium ascorbate (Standard); Sodium L-ascorbate (Standard); Vitamin C sodium salt (Standard)

    		 Reference Standards Calcium Channel Reactive Oxygen Species (ROS) Apoptosis Endogenous Metabolite Cancer
    L-Ascorbic acid (sodium salt) (Standard) is the analytical standard of L-Ascorbic acid (sodium salt). This product is intended for research and analytical applications. L-Ascorbic acid sodium salt (Sodium ascorbate), an electron donor, is an endogenous antioxidant agent. L-Ascorbic acid sodium salt selectively inhibits Cav3.2 channels with an IC50 of 6.5 μM. L-Ascorbic acid sodium salt is also a collagen deposition enhancer and an elastogenesis inhibitor [3].
    L-Ascorbic acid sodium salt (Standard)
  • HY-177955
    α-Obscurine derivative-1

    		Calcium Channel Drug Derivative Neurological Disease
    α-Obscurine derivative-1 (Compound 7) is a α-Obscurine (HY-134036) derivative. α-Obscurine derivative-1 inhibits CaV3.1 ion channel current with an IC50 of 0.19 μM. α-Obscurine derivative-1 can be used in the research of neurological disorders .
    α-Obscurine derivative-1
  • HY-B0166E
    L-Ascorbic acid magnesium

    L-Ascorbate magnesium; Vitamin C magnesium

    		 Reactive Oxygen Species (ROS) Calcium Channel Apoptosis Endogenous Metabolite Neurological Disease
    L-Ascorbic acid (L-Ascorbate) magnesium, an electron donor, is an endogenous antioxidant. L-Ascorbic acid selectively inhibits Cav3.2 channels with an IC50 of 6.5 μM. L-Ascorbic acid is also a collagen deposition promoter and elastin production inhibitor. L-Ascorbic acid exhibits anticancer effects by generating reactive oxygen species (ROS) and selectively damaging cancer cells [3] .
    L-Ascorbic acid magnesium
  • HY-156889
    Cav 3.1 blocker 1

    		Calcium Channel Neurological Disease
    Cav 3.1 blocker 1 (compound 12) is a T-type calcium channel blocker with an IC50value of 160 nM for Cav3.1. Cav 3.1 blocker 1 weakly inhibits Cav 3.2 (IC50 of 5000 nM), and shows no inhibition on Cav 3.3 and Cav 1.2 (IC50 of >10000 nM) .
    Cav 3.1 blocker 1
  • HY-126336
    HM12

    		Calcium Channel Cardiovascular Disease Neurological Disease
    HM12 is a covalent inhibitor of L-/T-type calcium channels. HM12 can strongly inhibit the Cav1.2 (L-type) and Cav3.2 (T-type) calcium channels, and has selectivity for the N-type channels. HM12 produces an irreversible inhibition that persisted after washout. HM12 can be used to study diseases such as hypertension, pain, epilepsy, etc .
    HM12
  • HY-154832
    Cav 3.2 inhibitor 4

    		Calcium Channel Cardiovascular Disease
    Cav 3.2 inhibitor 4 (compound 21) is a potent, peripherally restricted, selective T-type calcium channel (Cav3.2) inhibitor, with an IC50 of 0.6 μM. Cav 3.2 inhibitor 4 can be used for the research of atrial fibrillation .
    Cav 3.2 inhibitor 4
  • HY-151451
    Cav 3.2 inhibitor 2

    		Calcium Channel Neurological Disease
    Cav 3.2 inhibitor 2 is a Cav3.2 T-type Ca 2+ channels inhibitor with an IC50 of 0.09339 μM under -80mV holding potential. Cav 3.2 inhibitor 2 potently suppresses T-channel-dependent somatic and visceral pain in mice. Cav 3.2 inhibitor 2 can be used for the research of intractable pain .
    Cav 3.2 inhibitor 2
  • HY-50707
    (Rac)-TTA-P2

    (Rac)-T-Type calcium channel inhibitor

    		 Calcium Channel Drug Isomer Neurological Disease
    (Rac)-TTA-P2 is the isomer of TTA-P2 (HY-10035), and can be used as an experimental control. TTA-P2 (T-Type calcium channel inhibitor) is a potent inhibitor of T-Type calcium channel. TTA-P2 penetrates well the CNS and blocks the native T-type currents in deep cerebellar nuclear neurons, the window current is completely abolished both for wild-type and mutant Cav3.1 channels. TTA-P2 has the potential for the research of neurology disease .
    (Rac)-TTA-P2
  • HY-P1441A
    Mambalgin 1 TFA

    		Sodium Channel Neurological Disease
    Mambalgin 1 TFA is a selective ASIC1a inhibitor (IC50 values are 192 and 72 nM for human ASIC1a and ASIC1a/1b dimer, respectively). Mambalgin 1 TFA binds to closed/inactive channel. Mambalgin 1 TFA is selective for ASIC1a over ASIC2a, ASIC3, TRPV1, P2X2, 5-HT3, Nav1.8, Cav3.2 and Kv1.2 channels. Mambalgin 1 TFA increases latency of withdrawal response in mouse tail-flick and paw-flick tests.
    Mambalgin 1 TFA
  • HY-103309A
    ML218 hydrochloride

    		Calcium Channel Neurological Disease
    ML218 hydrochloride is a potent, selective and orally active T-type Ca 2+ channels (Cav3.1, Cav3.2, Cav3.3) inhibitor with IC50s of 310 nM and 270 nM for Cav3.2 and Cav3.3, respectively. ML218 hydrochloride inhibits the burst activity in subthalamic nucleus (STN) neurons. ML218 hydrochloride has no significant inhibition of L- or N-type calcium channels, KATP or hERG potassium channels. ML218 hydrochloride can penetrate the blood-brain barrier .
    ML218 hydrochloride
  • HY-122201
    NSC156529

    		Calcium Channel Neurological Disease Cancer
    NSC156529 is a potent T-type calcium-channel antagonist. NSC156529 shows inhibits on Cav3.1 and Cav3.2 and o Cav3.3 without effect. NSC156529 has the potential for the research of neuropsychic and genital system diseases .
    NSC156529
  • HY-103309S
    ML218-d9

    		Calcium Channel Neurological Disease
    ML218-d9 is the deuterium labeled ML218. ML218 is a potent, selective and orally active T-type Ca2+ channels (Cav3.1, Cav3.2, Cav3.3) inhibitor with IC50s of 310 nM and 270 nM for Cav3.2 and Cav3.3, respectively. ML218 inhibits the burst activity in subthalamic nucleus (STN) neurons. ML218 has no significant inhibition of L- or N-type calcium channels, KATP or hERG potassium channels. ML218 can penetrate the blood-brain barrier .
    ML218-d9
  • HY-147708
    T-Type calcium channel inhibitor 2

    		Calcium Channel Cancer
    T-Type calcium channel inhibitor 2 (compound 6g) is a potent T-type calcium channel inhibitor with IC50s of 31.0, 83.1, 69.3 µM for Cav3.1 (α1G), Cav3.2 (α1H), Cav3.3 (α1I) (α1H), respectively. T-Type calcium channel inhibitor 2 shows cytotoxicity for A549, HCT-116 cells with IC50s of 5.0, 6.4 µM, respectively .
    T-Type calcium channel inhibitor 2
  • HY-118030
    RQ-00311651

    		Calcium Channel Neurological Disease
    RQ-00311651 is a T-type calcium channel blocker that specifically targets the Cav3.2 isoform with a role in neuropathic and visceral pain. RQ-00311651 significantly inhibits T currents in HEK293 cells expressing human Cav3.1 or Cav3.2. RQ-00311651 also inhibited high potassium-induced calcium signaling. RQ-00311651 also inhibits antiallergic properties in rats and mice with neuropathic pain induced by spinal nerve injury or Paclitaxel (HY-B0015). Oral and intraperitoneal injection (10-20 mg/kg) inhibits Cerulein (HY-A0190)-induced acute pancreatitis and cyclophosphamide-induced cystitis in mice .
    RQ-00311651
  • HY-P5869
    Kurtoxin

    		Calcium Channel Sodium Channel Neurological Disease
    Kurtoxin is a selective Cav3 (T-type) voltage-gated Ca 2+ channel gating inhibitor with a Kd of 15 nM for Cav3.1 (α1G T-type) Ca 2+ channel. Kurtoxin can interact with high affinity with native neuronal high-threshold L-type, N-type, and P-type Ca 2+ channels in central and peripheral neurons. Kurtoxin also shows cross-reactivity with voltage-gated Na + channel .
    Kurtoxin
  • HY-P5793
    GTx1-15

    		Sodium Channel Calcium Channel Neurological Disease
    GTx1-15 is an inhibitor cystine knot (ICK) peptide that inhibits the voltage-dependent calcium channel Cav3.1 and the voltage-dependent sodium channels Nav1.3 and Nav1.7 .
    GTx1-15
  • HY-B0166S4
    L-Ascorbic acid-13C-3

    L-Ascorbate-13C-3; Vitamin C-13C-3

    		 Apoptosis Calcium Channel Endogenous Metabolite Reactive Oxygen Species (ROS) Neurological Disease Metabolic Disease Cancer
    L-Ascorbic acid- 13C-3 is the 13C labeled L-Ascorbic acid. L-Ascorbic acid (L-Ascorbate), an electron donor, is an endogenous antioxidant agent. L-Ascorbic acid inhibits selectively Cav3.2 channels with an IC50 of 6.5 μM. L-Ascorbic acid is also a collagen
    L-Ascorbic acid-13C-3
  • HY-147639
    Cav 2.2/3.2 blocker 1

    		Calcium Channel Neurological Disease
    Cav 2.2/3.2 blocker 1 (Compound 9e) is a neuronal calcium channel blocker with IC50 values of 78 μM and 80 μM against Cav2.2 and Cav3.2, respectively. Cav 2.2/3.2 blocker 1 can penetrate the CNS .
    Cav 2.2/3.2 blocker 1
  • HY-112499S1
    Menaquinone-7-13C6

    Vitamin K2-7-13C6; Vitamin K2(35)-13C6; Vitamin MK-7-13C6

    		 Isotope-Labeled Compounds Cardiovascular Disease
    Menaquinone-7- 13C6 is the 13C-labeled Menaquinone-7. Menaquinone-7 (Vitamin K2-7), belongs to a class of K2-vitamin homologs, is originally discovered as the anti-hemorrhagic factors . Menaquinone-7 (Vitamin K2-7) is identified as the most bioactive cofactor for the carboxylation reaction of Gla-proteins . Supplementation with Menaquinone-7 (Vitamin K2-7) is a pharmacological option for activating matrix Gla protein and intervening in the progression of calcific aortic valve stenosis (CAVS) .
    Menaquinone-7-13C6
  • HY-10035A
    (R)-TTA-P2

    		Calcium Channel Neurological Disease
    (R)-TTA-P2 is the isomer of TTA-P2 (HY-10035), and can be used as an experimental control. TTA-P2 (T-Type calcium channel inhibitor) is a potent inhibitor of T-Type calcium channel. TTA-P2 penetrates well the CNS and blocks the native T-type currents in deep cerebellar nuclear neurons, the window current is completely abolished both for wild-type and mutant Cav3.1 channels. TTA-P2 has the potential for the research of neurology disease .
    (R)-TTA-P2
  • HY-151450
    Cav 3.2 inhibitor 1

    		Calcium Channel Neurological Disease Inflammation/Immunology
    Cav 3.2 inhibitor 1 is a T-type calcium channel inhibitor with little binding affinity to dopamine D2 receptors. Cav 3.2 inhibitor 1 can be used for the research of somatic and visceral pain .
    Cav 3.2 inhibitor 1
  • HY-115681R
    (2R/S)-6-PNG (Standard)

    6-Prenylnaringenin (Standard); (±)-6-Prenylnaringenin (Standard)

    		 Reference Standards Calcium Channel Neurological Disease
    (2R/S)-6-PNG (Standard) is the analytical standard of (2R/S)-6-PNG. This product is intended for research and analytical applications. (2R/S)-6-PNG (6-Prenylnaringenin) is a potent and reversible Cav3.2 T-type Ca2+ channels (T-channels) blocker. (2R/S)-6-PNG can penetrate the blood-brain barrier (BBB). (2R/S)-6-PNG suppresses neuropathic and visceral pain in mice .
    (2R/S)-6-PNG (Standard)
  • HY-133794R
    Dasatinib N-oxide (Standard)

    		Reference Standards Drug Metabolite Cancer
    L-Ascorbic acid (GMP Like) (Standard) is the analytical standard of L-Ascorbic acid (GMP Like). This product is intended for research and analytical applications. L-Ascorbic acid (GMP Like) is the GMP Like class L-Ascorbic acid (HY-B0166). L-Ascorbic acid (L-Ascorbate, Vitamin C), an electron donor, is an endogenous antioxidant agent. L-Ascorbic acid inhibits selectively Cav3.2 channels with an IC50 of 6.5 μM. L-Ascorbic acid is also a collagen deposition enhancer and an elastogenesis inhibitor [3]. L-Ascorbic acid exhibits anti-cancer effects through the generation of reactive oxygen species (ROS) and selective damage to cancer cells .
    Dasatinib N-oxide (Standard)
  • HY-132184S
    5,6-Epoxyeicosatrienoic acid-d11

    5,6-EET-d11; (±)5,6-EpETrE-d11

    		 Isotope-Labeled Compounds Adrenergic Receptor Cardiovascular Disease Neurological Disease
    5,6-Epoxyeicosatrienoic acid-d11 (5,6-EET-d11) is deuterium labeled 5,6-Epoxyeicosatrienoic acid. 5,6-Epoxyeicosatrienoic acid is one of the four major epoxyeicosatrienoic acid (EET) isomers metabolized from Arachidonic acid (HY-109590). 5,6-Epoxyeicosatrienoic acid induces peripheral vasodilation and lowers blood pressure by inhibiting T-type calcium channels (Cav3.2: IC50 = 0.54 μM). 5,6-Epoxyeicosatrienoic acid causes vasoconstriction in hypoxic pulmonary blood vessels via activating Rho kinase in a membrane depolarization-dependent manner. 5,6-Epoxyeicosatrienoic acid induces mechanical pain by activating TRPA1. 5,6-Epoxyeicosatrienoic acid can be used in studies related to hypoxic pulmonary vasoconstriction, mechanical hyperalgesia and hypertension.
    5,6-Epoxyeicosatrienoic acid-d11
  • HY-103309R
    ML218 (Standard)

    		Reference Standards Calcium Channel Neurological Disease
    ML218 (Standard) is the analytical standard of ML218 (HY-103309). This product is intended for research and analytical applications. ML218 is a potent, selective and orally active T-type Ca2+ channels (Cav3.1, Cav3.2, Cav3.3) inhibitor with IC50s of 310 nM and 270 nM for Cav3.2 and Cav3.3, respectively. ML218 inhibits the burst activity in subthalamic nucleus (STN) neurons. ML218 has no significant inhibition of L- or N-type calcium channels, KATP or hERG potassium channels. ML218 can penetrate the blood-brain barrier .
    ML218 (Standard)
  • HY-129841
    Niguldipine monohydrochloride

    		Calcium Channel P-glycoprotein Cancer
    Niguldipine monohydrochloride is a calcium channel blocker that inhibits P-glycoprotein and can be used in tumor research. Niguldipine monohydrochloride inhibits Cav 3.2, with an IC50 of 0.9 μM .
    Niguldipine monohydrochloride

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: